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Abstract  32 
Objectives: Irregular menstrual cycles are associated with increased cardiovascular mortality. 33 
Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; 34 
androgens are drivers of increased metabolic risk in women with PCOS. Combined oral 35 
contraceptives (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically 36 
active androgen fraction. We examined the impact of COCP use on the risk of dysglycemia (pre-37 
diabetes and type 2 diabetes) in women with PCOS. 38 
Research Design and Methods: Utilizing a large UK primary care database (The Health 39 
Improvement Network, THIN; 3.7 million patients from 787 practices), we carried out a 40 
retrospective population-based cohort study to determine dysglycemia risk (64,051 women with 41 
PCOS, 123,545 matched controls), as well as a nested pharmaco-epidemiological case-control 42 
study to investigate COCP use in relation to dysglycemia risk (2407 women with PCOS with 43 
[=cases] and without [=controls] a diagnosis of dysglycemia during follow-up). Cox models were 44 
used to estimate the unadjusted and adjusted hazard ratio and conditional logistic regression was 45 
used to obtain adjusted odds ratios (aORs). 46 
Results: The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78- 47 
1.97, p<0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with 48 
increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a 49 
reduced dysglycemia risk (aOR 0.72, 95% CI 0.59 to 0.87). 50 
Conclusions: In this study limited by its retrospective nature and the use of routinely collected 51 
electronic general practice record data, which does not allow to exclude the impact of prescription-52 
by- indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia 53 
across all BMI subgroups. Future prospective studies should be considered to further understand 54 
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these observations and potential causality.  55 
 5 
Introduction 56 
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women (1) and is 57 
defined by irregular menses and androgen excess. Whilst previously mostly perceived as a 58 
reproductive disorder, PCOS is now recognized as a lifelong metabolic disorder with an increased 59 
prevalence of the cardiovascular risk factors insulin resistance, dyslipidemia and hypertension  (2–60 
4).  An increased risk of type 2 diabetes in women with PCOS has been described in both cross-61 
sectional (5) and cohort studies (5,6), the latter reporting a 2- to 4-fold increased risk, with type 2 62 
diabetes diagnosed on average four years earlier in women with PCOS than in the background 63 
population (7). In a population-based cohort study, women with PCOS were also found to have an 64 
increased risk of non-alcoholic fatty liver disease (NAFLD) (3), a major cardiovascular risk factor. 65 
A recently published prospective cohort study (8) in nearly 80,000 women with a follow-up period 66 
of 24 years described an increased risk of premature mortality, primarily due to cardiovascular 67 
disease, in women with irregular and long menstrual cycles, suggestive of PCOS as the major 68 
underlying risk factor. 69 
Androgen excess is a cardinal feature of PCOS (1) and its severity has been shown to correlate 70 
with insulin resistance in cross-sectional studies (9–11). In the general population, type 2 diabetes 71 
risk in women increases with circulating androgen concentrations and decreasing concentrations 72 
of sex-hormone binding globulin (SHBG) (12–15). Androgens have also been identified as a major 73 
risk factor for the development of NAFLD in PCOS, independent of body weight (3). Combined 74 
oral contraceptive pills (COCPs) are widely prescribed in women with PCOS for menstrual cycle 75 
regulation. In addition, COCPs can exert anti-androgen effects through two distinct mechanisms. 76 
The estrogen component in COCPs increases the production of SHBG in the liver, thereby 77 
reducing the concentration of free testosterone capable of binding and activating the androgen 78 
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receptor in target tissues of androgen action (16). Furthermore, some progestins used in COCPs 79 
can convey additional anti-androgenic action through androgen receptor blockade, namely 80 
cyproterone and drospirenone, while other progestins are pro-androgenic or exert no effect on the 81 
androgen receptor.  82 
Data on the impact of COCP prescription on glucose metabolism in women are conflicting. 83 
Clinicians have previously raised concerns that COCP intake may adversely impact on glucose 84 
metabolism (17) ; however available evidence is limited by a lack of prospective studies, and by 85 
the confounding issue of higher ethinylestradiol content in historical formulations. Furthermore, a 86 
wide diversity of combined oral contraceptive formulations available, including differences in 87 
progestin components, makes an accurate assessment of the impact of COCP prescription on 88 
glycemia very challenging. A recent Cochrane library review concluded that current evidence 89 
suggests no significant impact on carbohydrate metabolism in women without PCOS, highlighting 90 
a paucity of large-scale prospective studies to adequately address the question (18). Conversely, it 91 
has been hypothesized that the impact of COCP on carbohydrate metabolism may be protective 92 
against incident dysglycemia, due to the impact both of raising SHBG levels and of partial 93 
androgen receptor blockade in selected formulations containing antiandrogenic progestins.  94 
Here we tested the hypothesis that the use of COCPs decreases the risk of type 2 diabetes in women 95 
with PCOS. To this end, undertaking a population-based cohort study, we first determined the risk 96 
of incident dysglycemia, i.e. a composite outcome combining pre-diabetes and type 2 diabetes, in 97 
women with PCOS, and then examined in a nested pharmaco-epidemiological case-control study 98 
whether COCP intake impacts on this risk. 99 
 100 
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Research Design and Methods 101 
Data Source  102 
Datasets were derived from a UK primary care database, The IQVIA Medical Research Data (also 103 
known as The Health Improvement Network (THIN) database) has over 17 million patient records 104 
from 787 general practices (19). THIN uses Read codes, a hierarchical coding system for recording 105 
symptoms and diagnoses, and is highly suited for assessing chronic health conditions (3,12,20).   106 
Study Population 107 
Our study population were women aged 18 to 50 years during the study period (1st January 2000 108 
to 31st January 2017). Women were eligible one year after registration with their general practice 109 
or from the time their practice became eligible for THIN participation(3).  110 
Study designs 111 
PCOS and incident dysglycemia: This matched cohort study considered women with PCOS as 112 
exposed. Exposure was ascertained by Read codes for “Polycystic ovary syndrome (PCOS)” or 113 
“Polycystic ovaries (PCO)” (3), as this composite code list reflects community prevalence (21). 114 
Each exposed woman was matched with up to two women without PCOS within the same general 115 
practice for age (±2 years) and BMI (±2 kg/m2) (22,23).  116 
Follow-up start date or the index date for the exposed patients were set to PCOS diagnosis date for 117 
incident PCOS patients or patient eligibility date for prevalent PCOS patients (patients with a 118 
diagnosis ahead of cohort entry). The index date for a matched control was set to the corresponding 119 
index date of the exposed patient to mitigate immortality time bias (24). Follow-up occurred until 120 
the earliest occurrence of: (1) outcome, (2) study end or (3) patient censorship denoted by death, 121 
deregistration from the practice, or practice withdrawing from the THIN database.  122 
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Outcomes were type 2 diabetes and dysglycemia, the latter defined as the composite outcome of 123 
prediabetes and type 2 diabetes, which were ascertained by Read codes and laboratory results (type 124 
2 diabetes: HbA1c ≥6.5% (48 mmol/mol), fasting blood glucose ≥7 mmol/L; dysglycemia: HbA1c 125 
≥6.0% (42 mmol/mol), fasting blood glucose ≥6 mmol/L, random blood glucose ≥11.1 mmol/L, 126 
and 2h OGTT indicated as “abnormal” or “high”). Patients with a recording of the outcome of 127 
interest (dysglycemia) or glucose lowering drug prescription at baseline were not eligible. 128 
Risk factors of type 2 diabetes and dysglycemia among women with PCOS: To identify potential 129 
risk factors for the development of type 2 diabetes and dysglycemia within the PCOS cohort, we 130 
examined demographic risk factors, BMI, clinical features of androgen excess and prescription of 131 
COCPs at baseline as candidate risk factors.  132 
Combined oral contraceptives and incident dysglycemia among women with PCOS: To define 133 
the impact of COCPs on dysglycemia risk, we conducted a nested case-control study. Women who 134 
developed (dysglycemia during the follow-up period were cases and the remaining women were 135 
potential controls. One control per case was randomly selected after matching for age (±2 years), 136 
BMI (±2 kg/m2), PCOS diagnosis date (±2 years) and whether PCOS was diagnosed before or 137 
after the patient became eligible to take part in the study. Index date was assigned as the date of 138 
diagnosis of dysglycemia for the cases and the same date was assigned to the corresponding 139 
control, ensuring   comparable exposure window for matched case-control pairs and, therefore, 140 
avoiding time-window bias (25).  141 
The exposure window was pre-specified and extended from one year prior to cohort entry, to avoid 142 
disregarding valid prescriptions in the immediate period after patient registration, and six months 143 
prior to index date, to exclude prescriptions that cannot be validly attributed to the development of 144 
dysglycemia. 145 
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COCP prescription was initially considered as a binary variable. COCP prescription was then 146 
categorized according to whether or not the respective progestin component exerts anti-androgen 147 
activity. Patients with no prescription of COCP formed the reference groups for both the 148 
categorical exposure variables.  149 
Analysis 150 
Crude incidence rates of the primary and secondary composite outcome (type 2 diabetes and 151 
dysglycemia) were estimated per 10,000 person-years. Unadjusted and adjusted hazard ratios were 152 
obtained using Cox- model. Covariates for adjustment were selected based on biological 153 
plausibility for confounding.  154 
Socio-economic status was presented using Townsend score (26–28). Ethnicity was categorized 155 
based on UK 2011 census classification. Smoking status was categorized as currently smoking, 156 
discontinued and never smoked. Selection of Read Code lists exposure, outcome and covariates 157 
were based on methods and codes set out in previous publications (3,12,20,29) (Suppl Table 1). 158 
BMI was categorized as per WHO guidelines, with non-standard BMI categorization of South 159 
Asian women as per the recommended guidelines (30). 160 
Sensitivity Analyses 161 
Sensitivity analyses were performed to assess the extent of misclassification and survival bias. The 162 
exposure was, firstly, restricted to women with PCOS-specific diagnostic codes and, secondly, to 163 
those with a PCOS diagnosis during the study period (incident patients) (31). 164 
In addition, in the nested-case control study, we investigated if control selection based on risk set 165 
sampling altered our findings, allowing a patient to serve as a control for multiple patients 166 
diagnosed with dysglycemia while patients not diagnosed with dysglycemia at the similar time of 167 
follow-up could serve as controls before they developed dysglycemia. 168 
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Subgroup analyses 169 
To check if risk of type 2 diabetes and dysglycemia are independent of BMI status, we conducted 170 
subgroup analyses within each BMI category.  171 
Analyses for predictors of dysglycemia 172 
In the cohort restricted to women with PCOS, Cox regression analysis was used to identify 173 
statistically significant predictors of type 2 diabetes and dysglycemia. In addition to covariates 174 
mentioned in the primary analysis, prescription of COCPs and variables characteristic of androgen 175 
excess and prescription of anti-androgen therapy with single agent drugs were also considered as 176 
candidate predictors.  177 
Analysis of nested case-control study 178 
Conditional logistic regression was performed to obtain unadjusted and adjusted ORs for 179 
dysglycemia based on exposure to COCP. The adjusted model included all covariates in the 180 
primary analysis, plus prescription of metformin and anti-androgen therapy.   181 
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Results 182 
Study population characteristics 183 
64,051 women with PCOS and 123,545 women without PCOS and matched for age, sex and 184 
general practice were included in the study (Suppl. Figure 1, Table 1). The median follow-up 185 
period was 3.5 years [interquartile range (IQR) 1.4-7.2 years]. Mean age of the whole cohort was 186 
30.5 (SD 7.1) years, median BMI 25.6 (IQR 22.1-31.4) kg/m2, respectively. Age, BMI, 187 
deprivation 188 
quintiles (Townsend index) and smoking status had no apparent imbalance in distribution between 189 
the two groups. Women with PCOS were more likely to be documented as South Asians (4.8 vs 190 
2.9%), hypothyroid (3.4% vs 2.1%), and hypertensive (2.2% vs 1.6%) at baseline (Table 1). 191 
COCPs were prescribed for 43.4% of the PCOS exposed women before the index date; 22.5% of 192 
the women with PCOS were prescribed COCPs with an anti-androgenic progestin component 193 
(drospirenone or cyproterone acetate) (Table 1). 194 
Risk of type 2 diabetes and dysglycemia 195 
In the primary analysis, the incidence rate of type 2 diabetes among the exposed and the unexposed 196 
were 48.7 and 22.8 per 10,000 person years during a median follow-up of 3.39 (IQR 1.34-7.16) 197 
and 3.47 (IQR 1.39 - 7.18), respectively, equating to a doubling in risk of type 2 diabetes among 198 
women with PCOS (HR 2.13, 95% CI 1.98 to 2.29, p<0.001). 199 
Adjustment for age, deprivation quintiles, BMI category, ethnicity, smoking status and 200 
hypothyroidism did not alter the estimated hazard ratio (aHR 2.04, 95% CI 1.89 to 2.20, p<0.001) 201 
(Suppl. Table 2). 202 
When analysing the effect of PCOS on the composite outcome (dysglycemia), a similar effect was 203 
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observed (aHR 1.87, 95% CI 1.78 to 1.97, p<0.001). The incidence rates of dysglycemia were 96.3 204 
and 49.4 per 10,000 person years among women with and without PCOS during a median follow-205 
up of 3.32 (IQR 1.32-7.03) and 3.44 (IQR 1.38 - 7.11), respectively (Suppl. Table 2). 206 
Sensitivity analysis 207 
The strength of association between PCOS and type 2 diabetes did not decrease when the analysis 208 
was restricted to women with incident diagnosis of PCOS (aHR 1.98, 95% CI 1.70 to 2.31, 209 
p<0.001) and to women with PCOS-specific codes (aHR 2.17, 95% CI 1.88 to 2.51, p<0.001). 210 
This was similarly observed for dysglycemia (Incident cohort: aHR 1.95, 95% CI 1.76-2.16, 211 
p<0.001; PCOS-specific cohort: aHR 1.93, 95% CI 1.75 to 2.13, p<0.001) (Suppl. Table 2).   212 
Subgroup analysis stratified by BMI 213 
In subgroup analyses, women with PCOS had an increased risk of type 2 diabetes in all BMI 214 
categories compared to women without PCOS in the same BMI category (Normal/Underweight 215 
category - BMI <23 kg/m2 among women of South Asian ethnicity / <25 kg/m2 among women of 216 
all other ethnic groups aHR 1.88, 95% CI 1.42 to 2.51, p<0.001; Overweight category - BMI 23- 217 
27.5 kg/m2 among women of South Asian ethnicity / 25-29.9 kg/m2 among women of all other 218 
ethnic groups: aHR1.92, 95% CI 1.56 to 2.35, p<0.001; Obesity category - BMI ≥27.5 kg/m2 219 
among women of South Asian ethnicity/ ≥30 kg/m2 among women of all other ethnic groups: aHR 220 
1.88, 95% CI 1.72 to 2.06, p<0.001) (Figure 1A). Similar findings were observed for the 221 
composite outcome (dysglycemia) (Figure 1A).  222 
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 Risk factors for type 2 diabetes and dysglycemia among women with PCOS 223 
When analyzing the cohort of women with PCOS to identify risk factors for type 2 diabetes, PCOS 224 
specific variables emerged as significant risk factors, namely anovulation (aHR 1.21, 95% CI 1.08 225 
to 1.35. p=0.001) and hirsutism (aHR 1.20, 95% CI 1.05 to 1.36, p=0.007). Conversely, 226 
prescription of COCPs emerged as a protective factor, with similar effects observed for COCPs 227 
with (aHR 0.84, 95% CI 0.73 to 0.97, p=0.020) and without an anti-androgenic progestin 228 
component (aHR 0.83, 95% CI 0.72 to 0.94, p=0.005). The same risk factors and protective factors 229 
were observed for the composite dysglycemia outcome (Suppl. Table 3). 230 
Nested case-control analysis - the effect of oral contraceptives on risk of dysglycemia 231 
Of the 64,051 women with PCOS in the base cohort, 0.45% (n=2,885) developed dysglycemia 232 
during follow-up who were assigned as the cases in the nested case-control study (Table 2). The 233 
remaining 61,166 (95.5%) women were considered as potential controls. 478 cases could not be 234 
matched to a control based on age, BMI, PCOS diagnosis date and incident/prevalent status of 235 
PCOS diagnosis. Therefore, our final analysis included 2,407 cases and corresponding 2,407 236 
matched controls.  237 
Mean age at index date was 38.9 (8.3) years and mean age at PCOS diagnosis was 28.8 (14.4) 238 
years and was similar between cases and controls. BMI at cohort entry was similarly distributed 239 
between cases and controls (mean (SD) 32.7 (7.0) vs 32.6 (7.0) kg/m2). Compared to controls, 240 
cases were more likely to be from a deprived background (Townsend 5: 17.0% vs 12.3%), more 241 
likely to be smokers (26.6% vs 20.8%) and of South Asian ethnicity (10.0% vs 3.2%). At cohort 242 
entry, there was also a higher proportion of cases with concurrent hypothyroidism (10.6% vs 7.8% 243 
in controls). Altogether, 679 (28.2%) cases and 815 (33.9%) controls were prescribed COCPs 244 
during the exposure window. Among those prescribed COCPs, the median COCP prescription 245 
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count per person during the exposure window was 3 (IQR 1 to 7). 246 
When adjusted for age, smoking status, BMI category, ethnicity, Townsend score, baseline 247 
hypothyroidism, hypertension and prescription of isolated anti-androgen drugs, metformin and 248 
lipid lowering medication at baseline, women with PCOS exposed to COCP were seen to have a 249 
reduced risk of dysglycemia (aOR 0.74, 95% CI 0.65 to 0.85, p<0.001). For every issued COCP 250 
prescription recorded within the exposure window, there was a 2% reduction in the odds of 251 
dysglycemia (aOR 0.98, 95% CI 0.96 to 0.99, p=0.004) (Figure 1B).  252 
When COCP prescription issue count was categorized as (1) no prescription, (2) prescription count 253 
≤3, and (3) prescription count >3 within the exposure window, a dose-responsive reduction in the 254 
risk of dysglycemia was observed (in reference to no prescription of COCP, aOR of dysglycemia 255 
when prescription count ≤3 = 0.80, 95% CI 0.67 to 0.96, p=0.017 and aOR when prescription 256 
count >3 = 0.67, 95% CI 0.55 to 0.81, p<0.001) (Figure 1B). 257 
Women with PCOS exposed to COCPs had a reduced risk of dysglycemia irrespective of the type 258 
of progestin component (COCPs with anti-androgenic progestin: aOR 0.76, 95% CI 0.63-0.91, 259 
p=0.003; COCPs with progestin without anti-androgen activity: aOR 0.72, 95% CI 0.59-0.87; 260 
p<0.001) (Figure 1B, Suppl. Table 4). 261 
Metformin prescription within the exposure window period was associated with increased risk of 262 
dysglycemia (metformin: aOR 1.50, 95% CI 1.24 to 1.81, p<0.001), suggestive of possible 263 
prescription-by-indication bias for those at increased risk. Findings in the sensitivity analysis 264 
incorporating a risk set sampling approach showed a similar result (aOR 0.76, 95% CI 0.63 to 265 
0.91, p=0.003).  266 
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Conclusions 267 
Employing a rigorous nested case-control pharmaco-epidemiological analysis we found that 268 
women with PCOS exposed COCPs had a reduced risk of developing dysglycemia across all BMI 269 
subgroups. Our study is also the largest to report glycemic outcomes in a primary care cohort of 270 
women with PCOS, demonstrating a two-fold increased risk of incident type 2 diabetes and 271 
dysglycemia in women with PCOS of any BMI. 272 
Our finding of an increased type 2 diabetes risk in women with PCOS is consistent with recent 273 
population studies from Denmark and Finland (7,32) and hospitalization data from Australia (33), 274 
all reporting a 2- to 4-fold increased type 2 diabetes risk in PCOS. Using the Australian 275 
Longitudinal Study on Women’s Health, Kakoly et al. demonstrated that a diagnosis of PCOS was 276 
one of the most influential predictors of incident type 2 diabetes in women, even after adjusting 277 
for BMI and family history (34). Few population studies have looked specifically at the composite 278 
outcome of dysglycemia, which takes into account a spectrum of impaired glucose regulation 279 
ranging from impaired glucose tolerance and impaired fasting glucose through to overt 280 
hyperglycemia (35,36). Crucially, our data highlight that normal weight women with PCOS were 281 
also at increased risk of type 2 diabetes and dysglycemia. This parallels our previous finding of 282 
increased NAFLD risk in normal weight women with PCOS (3), further challenging the notion 283 
that PCOS-related metabolic complications are only relevant in the context of obesity. 284 
These data suggest that, rather than obesity in isolation, PCOS-specific factors, including androgen 285 
excess, underpin the increased metabolic risk. Our study found that those women with PCOS and 286 
hirsutism, a clinical feature of androgen excess, had a further increased risk of dysglycemia. In a 287 
population-based cohort study using the same primary care population database, we previously 288 
documented an independent link between serum testosterone and incident diabetes risk in women 289 
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(12). We demonstrated that the risk of incident T2DM increased significantly in women with a 290 
serum testosterone levels above 1.5nmol/l compared to the reference cohort with levels <1nmol/l; 291 
the risk was two-fold higher in women with serum testosterone values >3.5nmol/l. We also 292 
demonstrated in a small cross-sectional cohort study that women with increased circulating 293 
androgen concentrations had a higher risk of an abnormal oral glucose tolerance test (OGTT) 294 
result, with the OGTT-derived insulin sensitivity index (ISI) correlating inversely with circulating 295 
androgen burden (9). A recent meta-analysis (37) demonstrated that women with increased serum 296 
testosterone had a 60% higher risk of type 2 diabetes than women with normal testosterone levels. 297 
Furthermore, a recent large-scale genome association study in 425,097 participants of the UK 298 
biobank demonstrated that the risk of type 2 diabetes in women increased in line with increasing 299 
circulating testosterone concentrations (15). 300 
The association between female androgen excess, insulin resistance and type 2 diabetes is 301 
undoubtedly complex. Insulin resistance promotes androgen excess by upregulating ovarian 302 
androgen generation and peripheral androgen activation in adipose tissue (38,39); the latter 303 
increases lipid accumulation in the adipocyte and, once adipocyte lipid storage capacity is 304 
exhausted, fatty acid overspill (39), which is intricately linked to metabolic dysfunction. 305 
Abnormalities in skeletal muscle metabolic function have also been described in PCOS, with 306 
altered muscle mitochondrial energy biogenesis in the context of androgen excess likely to drive 307 
disturbances in glucose metabolism (40,41). Rodent-based studies also support a direct role for 308 
androgens in pancreatic beta-cell dysfunction, driving insulin hypersecretion, oxidative injury and 309 
consequent beta cell failure (42). These data have recently been underpinned by a study utilizing 310 
human pancreatic islets, demonstrating that intracrine activation of testosterone to the most potent 311 
androgen, 5α-dihydrotestosterone (DHT) increases glucose-stimulated insulin secretion (43). 312 
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A recent cohort study (8) in nearly 80,000 women with a follow-up period of 24 years described 313 
an increased risk of premature mortality, primarily due to cardiovascular disease, in women with 314 
irregular cycles. COCPs are routinely used for menstrual cycle regulation in women with PCOS. 315 
Our study is the first population-based study investigating the hypothesis that COCPs might 316 
mitigate the risk of dysglycemia in women with PCOS, with anti-androgen activity conferred by 317 
an estrogen-mediated increase in SHBG as the proposed mechanism. Studies examining the impact 318 
of COCPs on glucose metabolism have reported conflicting results and most are limited by small 319 
participant numbers and significant heterogeneity in COCP use. A 2016 Korean population study 320 
of 6,554 postmenopausal women found those who took the COCP during their reproductive years 321 
for more than 6 months had a 37% increased risk of T2DM (44). However, a more recent study 322 
examining the NHANES database between 2007 and 2018 found that COCP use in over 6,000 323 
women aged 35-50 years who met matching criteria had a 29% reduced risk of T2DM compared 324 
to never-users (45). A further limitation is the tendency in previous studies to extrapolate data 325 
from otherwise healthy female patient groups to women with PCOS, who are likely to manifest a 326 
biologically distinct set of risk factors for dysglycemia. The first cohort of the Nurses’ Health 327 
Study followed 2276 healthy women for a median of 12 years from 1976 and found that risk of 328 
type 2 diabetes was increased by 10% in women with previous COCP use compared to those who 329 
never took the medication (46); however, these data reflect the use of older COCP preparations 330 
with higher ethinylestradiol concentrations between the 1970s and 1990s. A recent Cochrane 331 
library review found no convincing evidence of glycemic risk associated with COCP prescription 332 
in women without PCOS (18), while a 2011 meta-analysis of the limited evidence in women with 333 
PCOS suggested neither adverse nor beneficial impact of COCPs on glucose homeostasis (47). A 334 
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2017 systematic review and meta-analysis highlighted the urgent need for further studies to 335 
understand the relationship between glucose metabolism and COCP use in both lean and obese 336 
women with PCOS (48). Our study improves our understanding in this regard and indicates the 337 
need for prospective, randomized controlled trials on the impact of COCPs on the risk of type 2 338 
diabetes and dysglycemia. We found that following adjustment for confounding factors women 339 
with PCOS and COCP use had a 27% reduction in the relative risk of incident dysglycemia, with 340 
the highest reduction in patients receiving higher numbers of COCP prescriptions. When analyzed 341 
separately, women with PCOS and COCP use had a similarly reduced risk of dysglycemia when 342 
exposed to COCPs with and without anti-androgenic progestin components, suggesting that the 343 
estrogen-induced increase in SHBG may be the primary driver of the risk-mitigating effect. 344 
However, this finding is potentially limited by the lower number of patients receiving 345 
antiandrogenic COCPs. Cyproterone acetate and drospirenone are progestins with anti-androgenic 346 
properties, as opposed to progestins such as desogestrel or levonorgestrel which have neutral or 347 
pro-androgenic effects (49). While cyproterone acetate and drospirenone exert anti-androgen 348 
activity via androgen receptor blockade, their anti-androgen activity is considerably smaller than 349 
recently approved novel anti-androgens mainly employed in the treatment of prostate cancer (50). 350 
Our finding that women using metformin and women using single agent anti-androgen therapy 351 
had an increased risk of incident dysglycemia is very likely reflective of a confounding-by-352 
indication bias (51). Accordingly, the women with PCOS at highest risk of dysglycemia based 353 
onmetabolic or androgen phenotype may have been systematically prescribed metformin and 354 
single 355 
agent anti-androgen therapy. It is possible that our observation of reduced dysglycemia risk in 356 
women with PCOS on COCPs may also reflect a prescription-by-indication bias, whereby those 357 
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women with cardiovascular risk factors such as obesity, dyslipidemia and hypertension were less 358 
likely to have been prescribed the COCP. However, we believe that this is less likely from closer 359 
review of the data; in our nested pharmaco-epidemiological study, 26% of women had a BMI in 360 
the obese range, and one quarter of women with a BMI above 35kg/m2 took COCPs during the 361 
follow up period. We have also carefully adjusted our analysis for metabolic phenotype by 362 
including BMI, hypertension and dyslipidemia as variables. 363 
Our study has a number of notable limitations, including the above-mentioned prescription-by-364 
indication bias issues, and others that are common to retrospective data using electronic general 365 
practice databases. The definition of women with no PCOS was based on the absence of any Read 366 
code in relation to PCOS and not on systematic diagnostic assessment to exclude PCOS. Therefore, 367 
the proportion of women with PCOS was also much lower than the published community 368 
prevalence data for PCOS (52). Another limitation is that we used the Read code for polycystic 369 
ovaries (PCO) as indicative of PCOS. However, in a sensitivity analysis limited to women with 370 
PCOS Read codes we documented similar findings, excluding the use of the PCO Read code as a 371 
significant limitation. Higher testing rates for type 2 diabetes among women with PCOS may also 372 
have resulted in over-estimating the effect size, however, the effect size observed for type 2 373 
diabetes in our study is similar to existing literature (53). It was also not possible to adjust for more 374 
specific lifestyle factors such as physical activity, energy intake or fibre consumption within a 375 
large population database as utilized in the present study. To explore the possibility of right 376 
censoring bias, the median follow-up and the loss to follow-up pattern was compared between 377 
patients with and without PCOS. There was no systematic difference observed between the two 378 
groups and therefore the assumption of non-informative censoring was reasonable for the time-to-379 
event analysis in this study, limiting the possibility of right censoring bias. 380 
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In conclusion, we demonstrated that women with PCOS have a significantly increased risk of 381 
dysglycemia that persisted after adjusting for BMI, corroborating the recommendation that women 382 
with PCOS should be systematically screened for type 2 diabetes irrespective of body weight 383 
category. In our nested pharmaco-epidemiology study, we found that women with PCOS and 384 
exposure to COCPs had a lower risk of incident dysglycemia. Though the limitations of our study 385 
design preclude ascertainment of causality, we hypothesize that a beneficial effect of COPs might 386 
be conveyed by an estrogen-induced increase in hepatic SHBG production. This increase would 387 
result in a decrease in the biologically active, unbound circulating androgen fraction and this 388 
reduction in androgen excess could have metabolically beneficial effects including a decrease in 389 
risk of dysglycemia. However, to definitively establish causality a large-scale randomized trial 390 
evaluating the efficacy of COCPs in reducing the risk of dysglycemia in women with PCOS would 391 
be required, with careful comparison of the potential additional benefit of COCPs containing 392 
antiandrogenic progestin components.  393 
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Figure Legends 574 
Figure 1: Risk of type 2 diabetes and dysglycemia among 64,051 women with PCOS compared 575 
to 123,545 matched controls and according to BMI subgroup (population-based cohort study; 576 
Panel A). Adjusted odds ratio (aOR) for risk of dysglycemia according to the prescription of 577 
combined oral contraceptive pills (COCPs) (Panel B) overall and according to prescription counts 578 
and type of progestin component, respectively, in the nested pharmaco-epidemiological 579 
casecontrol 580 
study (2407 women with PCOS with a diagnosis of dysglycemia during follow-up [=cases] 581 
and 2407 women with PCOS without a diagnosis of dysglycemia [=controls]).582 
583 
 30 
Table 1: Baseline characteristics of the participants of the population-based cohort study 
  




Age in years [Mean (SD)] 30.4 (7.0) 30.5 (7.1) 
BMI in kg/m2 [Median (IQR)] 25.9 (22.2-31.9) 25.4 (22.0-30.8) 
BMI Categories in kg/m2 [n (%)]*   
    Normal/Underweight  23,490 (36.6) 48,360 (39.1) 
    Overweight  12,734 (19.8) 25,229 (20.4) 
    Obese  17,591 (27.5) 29,907 (24.2) 
    Missing 10,236 (16.0) 20,049 (16.2) 
Smoking status [n (%)]   
    Non-smoker 37,311 (58.3) 71114 (57.6) 
    Discontinued 9,044 (14.1) 16,285 (13.2) 
    Smoker 14,674 (22.9) 28,284 (22.9) 
    Missing 3,022 (4.7) 7,862 (6.4) 
Ethnicity [n (%)]   
    Caucasian 30,597 (47.8) 50.206 (40.6) 
    Black 1,464 (2.3) 2,636 (2.1) 
    Chinese 582 (0.91) 883 (0.7) 
    South Asian 3,085 (4.8) 3,517 (2.9) 
    Mixed Race 897 (1.4) 1,645 (1.3) 
    Missing 27,426 (42.8) 64,658 (52.3) 
Townsend deprivation score [n (%)]   
    1 (least deprived) 11,270 (17.6) 21,839 (17.7) 
    2 10,280 (16.1) 19,866 (16.1) 
    3 12,064 (18.8) 23,471 (19.0) 
    4 11,530 (18.0) 22,623 (18.3) 
    5 (most deprived) 8,182 (12.8) 16,186 (13.1) 
    Missing 10,725 (16.7) 19,560 (15.8) 
Baseline comorbidity [n (%)]   
    Hypothyroidism 2,172 (3.4) 2,585 (2.1) 
    Hypertension 1,420 (2.22) 2,030 (1.64) 
Baseline medication [n (%)]   
    Any COCP 27,768 (43.4) 66,332 (53.7) 
    COCP without anti-androgen 25,481 (39.8) 64,157 (51.9) 
    COCP with anti-androgenic progestin 14,437 (22.5) 12,336 (10.0) 
         Drospirenone 4,944 (7.7) 6,550 (5.3) 
         Cyproterone  11,069 (17.3) 7,305 (5.9) 
  Single agent anti-androgen therapy   
    Cyproterone 444 (0.69)  
    Other anti-androgen drugs^ 42 (0.07)  
Lipid lowering medication 410 (0.64) 534 (0.43) 
BMI - Body mass index; COCP - Combined Oral Contraceptive Pill; *Normal/Underweight: <23.5 kg/m² 
 31 
for patients of South Asian ethnicity & <25 kg/m² for patients of all other ethnic groups, Overweight: 
23.5-27.5 kg/m² for patients of South Asian ethnicity & 25-30 kg/m² for patients of all other ethnic 
groups, Obese= ≥27.5 kg/m² for patients of South Asian ethnicity & ≥30 kg/m² for patients of all other 
ethnic groups;^includes dutasteride, enzalutamide, finasteride, flutamide, and spironolactone ; ¬ PCOS 
relevant variablessummarized only for the PCOS exposed cohort; NOTE: Patients with impaired glucose 
regulation orglucose lowering drug prescription at baseline not included in the cohortNOTE: Patients with 
impaired glucose regulation or glucose lowering drug prescription at baseline not included in the cohort 
¬ PCOS relevant variables summarized only for the PCOS exposed cohort 
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Table 2: Baseline characteristics of women with PCOS included in the nested case-control study. Cases 
and controls are matched women with and without a diagnosis of dysglycemia during follow-up, 
respectively. 
Variable 
Women with PCOS 
and a diagnosis of 
dysglycemia (Cases)  
Women with 
PCOS and without 




Age at index date 
(age at dysglycemia diagnosis for cases) [Mean (SD)] 38.89 (8.32) 38.84 (8.27) 
Age at PCOS diagnosis [Mean (SD)] 28.84 (14.43) 28.76 (14.00) 
BMI (kg/m2) [Mean (SD)] 32.72 (6.98) 32.59 (7.03) 
BMI Categories [n (%)]   
    Normal/Underweight  270 (11.2) 305 (12.7) 
    Overweight  439 (18.2) 437 (18.2) 
    Obese  1,322 (54.9) 1,289 (53.5) 
    Missing 376 (15.6) 376 (15.6) 
Townsend deprivation score [n (%)]   
    1 (least deprived) 351 (14.6) 481 (20.0) 
    2 359 (14.9) 436 (18.1) 
    3 473 (19.7) 457 (19.0) 
    4 471 (19.6) 420 (17.5) 
    5 (most deprived) 408 (17.0) 295 (12.3) 
    Missing 345 (14.3) 318 (13.2) 
Smoking status [n (%)]   
    Non-Smoker 1,306 (54.3) 1,354 (56.3) 
    Discontinued 295 (12.3) 362 (15.0) 
    Smoker 639 (26.6) 501 (20.8) 
    Missing 167 (6.9) 190 (7.9) 
Ethnicity [n (%)]   
    Caucasian 999 (41.5) 1,099 (45.7) 
    Mixed Race 38 (1.6) 21 (0.87) 
    Chinese/middle eastern/others 21 (0.87) 13 (0.54) 
    Black 80 (3.3) 40 (1.7) 
    South Asian 241 (10.0) 77 (3.2) 
    Missing 1,028 (42.7) 1,157 (48.1) 
Concurrent Conditions at baseline [n (%)]   
    Hypothyroidism 256 (10.6) 188 (7.8) 
    Hypertension 623 (25.88) 179 (11.59) 
Prescription of drugs within the exposure time window [n (%)]  
  Contraceptives   
   No Pill 1,728 (71.8) 1,592 (66.1) 
   COCP without anti-androgenic progstin 301 (12.5) 389 (16.2) 
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   COCP with anti-androgenic progestin* 378 (15.7) 426 (17.7) 
  Single agent anti-androgen therapy ^ 41 (1.7) 23 (0.96) 
  Metformin 417 (17.3) 330 (13.7) 
  Lipid lowering medication 150 (6.23) 
119 (4.94) 
 
BMI - Body mass index; COCP - Combined Oral Contraceptive Pill; *Normal/Underweight: <23.5 
kg/m² for patients of South Asian ethnicity & <25 kg/m² for patients of all other ethnic groups, 
Overweight: 23.5-27.5 kg/m² for patients of South Asian ethnicity & 25-30 kg/m² for patients of all 
other ethnic groups, Obese = ≥27.5 kg/m² for patients of South Asian ethnicity & ≥30 kg/m² for 




Figure 1: Risk of type 2 diabetes and dysglycemia among 64,051 women with PCOS compared with 
123,545 matched control subjects and according to BMI subgroup (population-based cohort study [A]). 
aOR for risk of dysglycemia according to the prescription of COCPs (B) overall and according to 
prescription counts and type of progestin component, respectively, in the nested 
pharmacoepidemiological case-control study (2,407 women with PCOS with a diagnosis of dysglycemia 
during follow-up [case subjects] and 2,407 women with PCOS without a diagnosis of dysglycemia 
[control subjects]). Normal/underweight, <23.5 kg/m2 for patients of South Asian ethnicity and <25 
kg/m2 for patients of all other ethnic groups; overweight, 23.5–27.5 kg/m2 for patients of South Asian 
ethnicity and 25–30 kg/m2 for patients of all other ethnic groups; and obese, ≥27.5 kg/m2 for patients of 
South Asian ethnicity and ≥30 kg/m2 for patients of all other ethnic groups.  
